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Murine tumor models that closely reﬂect human diseases are important tools to investigate carcinogenesis and
tumor immunity. The transgenic (tg) mouse strain tg(Grm1)EPv develops spontaneous melanoma due to ectopic
overexpression of the metabotropic glutamate receptor 1 (Grm1) in melanocytes. In the present study, we
characterized the immune status and functional properties of immune cells in tumor-bearing mice. Melanoma
development was accompanied by a reduction in the percentages of CD4+ T cells including regulatory T cells
(Tregs) in CD45+ leukocytes present in tumor tissue and draining lymph nodes (LNs). In contrast, the percentages
of CD8+ T cells were unchanged, and these cells showed an activated phenotype in tumor mice. Endogenous
melanoma-associated antigen glycoprotein 100 (gp100)-speciﬁc CD8+ T cells were not deleted during tumor
development, as revealed by pentamer staining in the skin and draining LNs. They, however, were unresponsive
to ex vivo gp100-peptide stimulation in late-stage tumor mice. Interestingly, immunosuppressive myeloid-
derived suppressor cells (MDSCs) were recruited to tumor tissue with a preferential accumulation of
granulocytic MDSC (grMDSCs) over monocytic MDSC (moMDSCs). Both subsets produced Arginase-1,
inducible nitric oxide synthase (iNOS), and transforming growth factor-β and suppressed T-cell proliferation
in vitro. In this work, we describe the immune status of a spontaneous melanoma mouse model that provides an
interesting tool to develop future immunotherapeutical strategies.
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INTRODUCTION
Clinically relevant animal models of melanoma that mimic
the human situation are crucial for investigations of tumor
etiology and immunology. Chen et al. (1996) came across a
spontaneous melanoma model when they tried to generate a
mouse with adipocyte dysfunction. This strain, named LLA-
TG3, possessed multiple tandem insertions of a transgene in
the gene Grm1 encoding the metabotropic glutamate receptor
1 (Grm1), resulting in systemic overexpression. This led to the
persistence of melanocytes in skin areas without fur, e.g. ear
and tail skin, followed by hyperproliferation and subsequent
melanoma development (Chen et al., 1996; Cohen-Solal
et al., 2001). The signiﬁcance of Grm1 in tumorigenesis was
conﬁrmed by the generation of the tg(Grm1)EPv mouse
model, in which overexpression of Grm1 is driven by the
melanocyte-speciﬁc dopachrome tautomerase promoter
(Pollock et al., 2003). These mice spontaneously develop
melanoma with a 100% penetrance at the age of 4–6 months
in skin regions such as ear and tail skin. Tumors in tg(Grm1)
EPv mice do metastasize, as the presence of melanoma cells
in lymph nodes (LNs) has already been reported (Pollock
et al., 2003). Grm1-positive cells could also be detected in
lymphatic organs and in lung as well as liver; however, most
of these cells were non-pigmented (Schiffner et al., 2012). The
relevance of this pathway for human tumorigenesis was
substantiated by the fact that 460% of human melanoma
samples overexpress Grm1 (Namkoong et al., 2007).
Cancer immunosurveillance as proposed in 1957 by Burnet
controls both initial steps of carcinogenesis and cancer
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progression (Burnet, 1957). The immune system is able to
recognize and eliminate transformed cells, as demonstrated by
enhanced susceptibility to cancer when the immune system is
impaired (Dunn et al., 2002). The balance between effective
tumor immunity and tumor escape mechanisms decides on
the elimination or progression of cancer (Schreiber et al.,
2011). Cytotoxic effector cells such as T and natural killer cells
inﬁltrate tumor tissue to ﬁght tumor cells (Vesely et al., 2011;
Gajewski et al., 2013). One prerequisite for effective anti-
tumor immunity is the presentation of antigens by tumor cells
and their recognition by inﬁltrating cytotoxic CD8+ T cells. A
problem encountered with many tumor-associated antigens is
that they are poorly immunogenic non-mutated self-antigens.
A reason for their poor immunogenicity is tolerance induction
associated with the deletion or anergy of self-reactive CD8+
T cells during tumorigenesis (Willimsky and Blankenstein,
2007). In addition, tumors employ a complex immunosuppres-
sive network to escape immune recognition. Suppressive cells,
such as regulatory T cells (Tregs) and myeloid-derived sup-
pressor cells (MDSCs), inﬁltrate tumors and prevent anti-tumor
immune responses (Nishikawa and Sakaguchi, 2010;
Gabrilovich et al., 2012). These various immune evasion
mechanisms eventually result in an impaired function of cyto-
toxic CD8+ T cells and natural killer cells translating in a poor
prognosis for the patients (Schreiber et al., 2011; Motz and
Coukos, 2013). Despite this, CD8+ T cells speciﬁc for tumor-
associated self-antigens, such as glycoprotein 100 (gp100), tyro-
sinase, and MART, do exist in patients with malignant melanoma
(Bakker et al., 1994; Kawakami et al., 2000; Boon et al., 2006).
For this reason, clinical studies are using melanosomal antigens
for vaccination approaches (Rosenberg et al., 2004).
In the present study, we characterized the immunological
features of a spontaneous mouse melanoma model based on
Grm1 overexpression that can also be observed in about 60%
of human melanoma samples. Our results suggest that tumors
grow progressively despite the presence of activated T cells.
We found possible explanations for impaired tumor immu-
nity, including gp100-speciﬁc CD8+ T-cell anergy and the
inﬁltration of immunosuppressive MDSCs into the tumor
microenvironment.
RESULTS
The percentages of CD4+ T cells and Tregs are reduced in
late-stage tumors of tg(Grm1)EPv mice
The immunological status of the tg(Grm1)EPv mouse was
hitherto unknown; hence, we characterized the immune cells
present in tumor tissue and draining LNs. For this purpose, we
compared tumor-free mice (2–3 months of age) with mice
bearing early-stage (5–6 months) and late-stage tumors (8–
9 months; Supplementary Figure S1 online). Immunoﬂuores-
cence stainings of late-stage tumor sections revealed that
CD4+ and CD8+ T cells were present in the tumor and that a
proportion of CD4+ T cells co-expressed FoxP3-a marker for
Tregs (Supplementary Figure S2 online).
For quantiﬁcation of immune cells present in tumor-free
and tumor-bearing mice, ear skin and draining LNs were
enzymatically digested, and CD45+ cells were analyzed by
ﬂow cytometry. Because tumor growth in tg(Grm1)EPv mice
occurs progressively over several months, we also monitored
young (2–3 months) and old (8–9 months) C57BL/6 mice in
order to rule out that these observed changes were not solely
caused by aging (Supplementary Figure S3 online).
There was no change in the overall percentages of CD45+
cells in the skin of tumor-free, early-stage, and late-stage tumor
mice (Figure 1a), similar to what we observed in C57BL/6 mice
(Supplementary Figure S3a online). Less CD4+ T cells were
present in late-stage tumors (Figure 1b), a feature that was
clearly absent from old C57BL/6 mice (Supplementary Figure
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Figure 1. The percentages of CD4+ T cells and Tregs are reduced in late-stage tumors of tg(Grm1)EPv mice. Cell suspensions from the skin and draining lymph
nodes (LNs) of tumor-free, early-stage, and late-stage tumor tg(Grm1)EPv mice were analyzed by ﬂow cytometry. (a) Percentages of CD45+ leukocytes are shown
after pregating on viable cells (n=14 mice). For all further analyses, the percentages of cells were calculated based on CD45+ viable cells. (b and c) CD4+ and
CD8+ T cells were analyzed in (b) the skin (n= 8 mice) and (c) the draining LNs (n=15 mice). (d) Representative FACS plots for FoxP3+ CD25+ Tregs in the skin
and draining LNs of tumor-free mice. (e) Summary graph for the percentages of FoxP3+ CD25+ Tregs in the skin and draining LNs (n⩾8 mice).
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S3b online). Cutaneous CD8+ T cells were unaltered by tumor
development (Figure 1b), despite showing a slight increase
over aging in C57BL/6 mice (Supplementary Figure S3b
online). However, in LN draining either late-stage tumor of tg
(Grm1)EPv mice (Figure 1c) or the skin of aged C57BL/6 mice
(Supplementary Figure S3c online), we observed a comparable
reduction in CD4+ T cells, suggesting that this change might be
age related. In addition, we were able to detect CD4+ T cells
expressing the Treg marker FoxP3 in the skin and lymphoid
tissue of tg(Grm1)EPv mice (Figure 1d). The percentages of
Tregs in the total CD45+ cell pool were reduced in late-stage
tumor tissue and the draining LNs (Figure 1e), whereas these
proportions remained the same in young and old C57BL/6
mice (Supplementary Figure S3d online). Altogether, our data
suggest tumor-related reduction of CD4+ T cells including
Tregs in tumor tissue.
Activated T cells are present in late-stage tumor mice and can
produce IFN-γ
Because of the fact that percentages of T cells differed
between tumor-free and late-stage tumor tg(Grm1)EPv mice,
we assessed the phenotype and functional properties of
T cells in draining LNs of these mice. Tumor development
was accompanied by a signiﬁcant upregulation of the
activation marker CD44 and a reduction in the homing
receptor L-selectin (CD62L) on CD4+ and CD8+ T cells,
reﬂecting enhanced differentiation into CD44hi CD62Llow
effector memory T cells (Figure 2a). In addition, more T cells
upregulated the activation marker CD69 in draining LNs
when compared with tumor-free mice (Figure 2b). Next, we
determined whether tumor formation would alter the ability of
T cells to produce the cytokine IFN-γ. For this purpose, LN
cell suspensions were restimulated in vitro with antibodies
against CD3 and CD28. CD4+ T cells showed little IFN-γ, and
production was unchanged upon tumor development. In
contrast, more CD8+ T cells produced IFN-γ in draining LNs
of late-stage tumor mice (Figure 2c). Although similiar
activation patterns were detected in LNs of aged C57BL/6
mice indicating possible age-related effects (Supplementary
Figure S4 online), it is still interesting to note that activated
and functional T cells are present in the draining LNs of
tumor-bearing tg(Grm1)EPv mice.
Endogenous gp100-speciﬁc CD8+ T cells are present in tumor
mice but are functionally impaired upon antigen-speciﬁc
restimulation
Despite the presence of activated T cells in tumor-bearing tg
(Grm1)EPv mice, tumor growth cannot be controlled. To
better understand the mechanisms behind impaired tumor
immunity, we investigated T cells by pentamer staining with a
focus on the presence and functional properties of gp100-
speciﬁc CD8+ T cells (Figure 3a). We found that, in the skin
and draining LNs of tg(Grm1)EPv mice, the percentages of
gp100-speciﬁc CD8+ T cells were not affected by tumor
development (Figure 3b). In order to test the functional
properties of gp100-speciﬁc CD8+ T cells, we performed
antigen-speciﬁc in vitro restimulation of total LN cells with a
gp100 peptide. The percentages of gp100-responsive CD8+
T cells were determined by comparing the proportion of
CD8+ T cells producing IFN-γ upon gp100-peptide restimula-
tion related to the proportion of CD8+ T cells labeled by
major histocompatibility complex I/gp100 pentamer. This
calculation was necessary because IFN-γ–producing CD8+
T cells downregulate their TCR, which can therefore no longer
be detected in a reliable way by pentamer staining. In tumor-
free tg(Grm1)EPv mice, 60% of pentamer+ CD8+ T cells
produced IFN-γ, whereas T cells in late-stage tumor mice
were incapable of producing IFN-γ (Figure 3c and d). These
data suggest that, in late-stage tumor tg(Grm1)EPv mice,
gp100-speciﬁc CD8+ T cells are anergic to the melanocyte-
derived antigen gp100.
MDSCs accumulate in the skin and draining lymph nodes of
late-stage tumor mice
The reduction of Tregs in late-stage tumors of tg(Grm1)EPv
mice suggested a negligible role for inhibition of anti-tumor
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Figure 2. Activated T cells are present in late-stage tumor mice and produce
IFN-γ. Cell suspensions from draining lymph nodes (LNs) of tumor-free and
late-stage tumor tg(Grm1)EPv mice were analyzed by ﬂow cytometry. All
analyses used a pregate on CD45+ viable cells. CD4+ and CD8+ T-cell subsets
in draining LNs were analyzed for the following: (a) CD44hi CD62Llow T cells
(n=11 mice) and (b) CD69+ activated T cells (n=8 mice). (c) IFN-γ-producing
T cells were analyzed after restimulation of LN cells with antibodies against
CD3 and CD28 for 48 h (n⩾6 mice).
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immune responses by this cell type. Another population of
immunosuppressive cells, namely MDSCs, are capable of
suppressing immune responses against tumors, thereby
allowing tumor escape (Gabrilovich et al., 2012). We
investigated CD11b+ Gr-1+ MDSCs in the skin and draining
LNs of tumor-free, early-stage, and late-stage tumor mice. In
the skin, MDSCs accumulated in late-stage tumors, and, a
similar trend was observed in the tumor-draining LNs, albeit
not as pronounced as in the skin (Figure 4a and b). In an effort
to characterize CD11b+ Gr-1+ MDSC subsets, we analyzed
the percentages of CD11b+ Gr-1inter Ly-6Chigh monocytic
MDSCs (moMDSCs) and CD11b+ Gr-1high Ly-6Clow granulo-
cytic MDSCs (grMDSCs) in the skin and draining LNs of
tumor-free and late-stage tumor mice. Tumor development
led to an accumulation of both MDSC subsets in the skin and
draining LNs of tg(Grm1)EPv mice (Figure 4c and d). We
examined additional markers on MDSCs and detected higher
levels of M-CSF receptor (CD115) and major histocompat-
ibility complex class II on moMDSCs than on grMDSCs
(Supplementary Figure S5 online). In order to rule out that
MDSC inﬁltration was age related, we analyzed both MDSC
subsets in young and old C57BL/6 mice. No MDSC
accumulation was detected in both the skin and draining
LNs of aged C57BL/6 mice (Supplementary Figure S6 online).
Thus, accumulation of CD11b+ Gr-1+ cells in late-stage
tumors of tg(Grm1)EPv mice suggested an immunosuppres-
sive tumor microenviroment that favors tumor growth.
MDSCs in the tumor are potent suppressors of T-cell activity
In order to test the capacity of MDSCs to suppress T-cell
activity, we ﬂow cytometrically sorted MDSC subsets from the
skin of late-stage tumor tg(Grm1)EPv mice (Supplementary
Figure S7a online). We puriﬁed gp100-speciﬁc CD8+ T cells
from pmel-1 mice and cultured them with gp100-peptide–
loaded mature bone marrow–derived dendritic cells
(BMDCs). The gp100-speciﬁc CD8+ T cells proliferated in
response to peptide-loaded BMDCs, and the addition of
sorted moMDSCs or grMDSCs signiﬁcantly reduced T-cell
proliferation (Figure 5a). The suppression of T-cell function
was dependent on the number of MDSCs (Supplementary
Figure S7b online).
Next, we attempted to elucidate factors responsible for
MDSC-mediated immunosuppression and investigated the
expression of Arginase-1 and inducible nitric oxide synthase
(iNOS) in moMDSCs and grMDSCs sorted from late-stage
tumors. In addition, we examined transforming growth factor-
β (TGF-β), a cytokine that is considered to be one of the key
immunosuppressive factors released by tumors and MDSCs
(Gabrilovich and Nagaraj, 2009). Quantitative PCR (qPCR)
analysis of sorted MDSCs from tumors revealed high mRNA
levels for all three molecules and low to undetectable levels
in tumor cells and non-MDSC immune cells (Figure 5b–d). In
addition, we observed different expression patterns in the two
MDSC subsets, such that grMDSCs expressed higher mRNA
levels of iNOS (Figure 5c) and TGF-β (Figure 5d) but lower
levels of Arginase-1 compared with moMDSCs (Figure 5b).
This was conﬁrmed by intracellular ﬂow cytometric analysis
showing that more grMDSCs were positive for iNOS than for
Arginase-1 (Figure 5e–h). From this we conclude that
grMDSCs as the predominant immunosupressive population
in tumors of tg(Grm1)EPv mice most likely suppress T-cell
function by iNOS, TGF-β, and Arginase-1 production.
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Figure 3. Endogenous glycoprotein 100 (gp100)-speciﬁc CD8+ T cells are present in late-stage tumors but are functionally impaired upon antigen-speciﬁc
restimulation. Cell suspensions from the skin and draining lymph nodes (LNs) of tumor-free and late-stage tumor tg(Grm1)EPv mice were analyzed by ﬂow
cytometry for gp100-speciﬁc CD8+ T cells. All analyses used a pregate on CD45+ viable cells. (a) Representative FACS plots from a tumor-free tg(Grm1)EPv
mouse for pentamer+ CD8+ T cells in the skin and draining LNs, pregate on viable CD8+ T cells. (b) Summary graph for pentamer+ CD8+ T cells in the skin and
draining LNs (n⩾ 9 mice). (c) Representative FACS plots from a tumor-free tg(Grm1)EPv mouse for IFN-γ production of CD8+ LN cells cultured without (untreated)
or with gp100 peptide for 48 h. (d) Summary graph for gp100-responsive IFN-γ+ CD8+ cells calculated as following: ((mean of IFN-γ+ CD8+ cells restimulated
with gp100 peptide)− (mean of IFN-γ+ CD8+ cells cultured without gp100 peptide))/(mean of unstimulated pentamer+ CD8+ cells), n⩾4 mice.
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DISCUSSION
Transgenic (tg) mouse models based on genetic aberrations are
essential for an improved understanding of melanoma biology
and immunology (Becker et al., 2010). Here, we have
investigated the immune status of a murine melanoma model
based on ectopic overexpression of Grm1 in melanocytes. This
overexpression results in spontaneous tumor development and
established a link between metabotropic glutamate signaling in
melanocytes and melanoma development, reﬂecting the
relevance of this mouse model and the functional importance
of the glutamate pathway in cancer (Pollock et al., 2003;
Prickett and Samuels, 2012). In line with this, studies on
human tumor material revealed that Grm1 is aberrantly
expressed in 60% of human melanoma samples (Namkoong
et al., 2007). Over the last decade, several studies made use of
this murine melanoma model in order to better understand
the metastatic behavior of tumors and to test future
immunotherapeutical approaches (Marin et al., 2006; Xiao
et al., 2011; Schiffner et al., 2012). However, nothing was
known about the immune status of these mice. In this work, we
describe the composition of immune cells present in the skin
and draining LNs of tumor-free and tumor-bearing mice and
provide some clues on their functional role in tumor immunity.
We observed immunosuppression on two levels: (i) CD8+
T cells seemed to be anergic to the melanoma-associated
antigen gp100; (ii) MDSCs with the ability to suppress gp100-
speciﬁc CD8+ T-cell response represented the dominating
immune cell population in late-stage tumor tissue mediating
their suppressive effect by iNOS, TGF-β, and Arginase-1
production.
High prevalence of T cells in tumors is an indicator for
longer overall survival of advanced-stage melanoma patients
(Haanen et al., 2006; van Houdt et al., 2008). Therefore, we
characterized the composition of immune cells present in the
tumor microenvironment and the draining LNs to which
immune cells might relocate. When we investigated the
CD45+ cell pool, we observed that the CD8+ T-cell
frequencies were not affected by tumor growth, whereas the
percentages of CD4+ T cells including Tregs were
signiﬁcantly reduced in late-stage tumor mice. The CD4+
T-cell reduction in the draining LNs was also detectable in
aged C57BL/6 mice, indicating an age-related effect on
immune cell composition; however, all other alterations in
the precentages of immune cells in tg(Grm1)EPv mice were
tumor associated. Thus, our ﬁndings indicate that early- and
late-stage tumors are not inﬁltrated by T cells correlating with
a less immunogenic microenvironment (Gajewski et al.,
2013). The observed reduction in Tregs ﬁts to an earlier
report on the ret-tg mouse model for melanoma that
demonstrated recruitment of Tregs in early-stage tumors
followed by a decrease in Tregs in late-stage tumors
(Kimpﬂer et al., 2009). The authors also showed that
depletion of Tregs did not delay tumor development,
indicating an alternative source of immunosuppression. In
contrast, in a transplantable B16 melanoma mouse model, the
depletion of Tregs caused a partial regression of established
tumors (Klages et al, 2010). Hence, the mechanisms of
immunosuppression might differ between the various mouse
tumor models for melanoma.
The undisturbed tumor growth in the tg(Grm1)EPv mouse
model led us to hypothesize that the remaining lymphocytes
are compromised in mounting a proper immune response
against the tumor. In line with this, studies performed in
human melanoma patients and various murine melanoma
models suggested that lymphocytes are dysfunctional
(Ladanyi et al., 2004; Boon et al., 2006; Ahmadzadeh et al.,
2009; Fourcade et al., 2010; Landsberg et al., 2010).
Therefore, we characterized the activation status of T cells
present in the draining LNs of late-stage tumor mice. These
mice showed elevated percentages of CD44hi CD62Llow
CD4+ and CD8+ T cells. Enhanced activation was further
conﬁrmed by higher levels of the early activation marker
CD69 on both T-cell subsets. This implied that, similar to the
ret-tg melanoma mouse model (Umansky et al., 2008), tumor
growth is accompanied by T-cell differentiation into effector
memory T cells. In addition, CD8+ T cells from LN draining
late-stage tumors were able to produce IFN-γ upon in vitro
restimulation, indicating that they are not functionally
impaired. However, we cannot exclude that aging has some
effect due to similar ﬁndings in old C57BL/6 mice and reports
that showed an activated phenotype in T cells of aged mice
(Akbar and Henson, 2011). Nevertheless, the fact that tumor
growth cannot be contained by the immune system suggested
potent immune escape mechanisms.
Adaptive immunity against the tumor is conducted by
antigen-speciﬁc T cells. In the case of melanoma, the antigen
gp100 is expressed by melanocytes and upregulated during
tumor growth. This protein represents a tumor-associated
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Figure 4. Myeloid-derived suppressor cells (MDSCs) accumulate in the skin
and draining lymph nodes (LNs) of late-stage tumor mice. Cell suspensions of
tumor-free, early-stage, and late-stage tumor tg(Grm1)EPv mice were analyzed
by ﬂow cytometry for the presence of CD11b+ Gr-1+ MDSCs in (a) the skin
and (b) draining LNs (n=6 mice). MDSCs were further subdivided into
CD11b+ Gr-1inter Ly-6Chigh monocytic MDSCs (moMDSCs) and CD11b+
Gr-1high Ly-6Clow granulocytic MDSCs (grMDSCs) in tumor-free and late-stage
tumor tg(Grm1)EPv mice for (c) the skin and (d) the draining LNs (n=10 mice).
All analyses used a pregate on CD45+ viable cells.
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antigen that can be recognized by gp100-speciﬁc CD8+
T cells (Bakker et al., 1994; Boon et al., 2006; Rizzuto et al.,
2009). In tumor-free tg(Grm1)EPv mice, o0.5% of CD8+
T cells were speciﬁc for gp100 in the draining LNs as opposed
to 10–15% gp100-speciﬁc CD8+ T cells in the skin.
Tumorigenesis had no effect on the percentages of gp100-
speciﬁc CD8+ T cells; however, CD8+ T cells from LNs of
late-stage tumor mice were unresponsive to restimulation to
gp100 peptide in vitro. These ﬁndings suggest an anergic state
due to tolerance induction to the differentiation antigen
gp100. Similar to gp100, many tumor-associated antigens are
non-mutated self-proteins that represent attractive targets for
immunotherapy as they are shared between patients. How-
ever, a state of functional tolerance apparently exists (Boon
et al., 2006). Nevertheless, it has been reported that
immunization with gp100 can induce cytotoxic T-cell
responses in murine melanoma models (Overwijk et al.,
2003; Xiao et al., 2011) and has been used in clinical trials to
treat cancer patients (Rosenberg et al., 2004). In order to
generate anti-tumor immune response against gp100, potent
immunization approaches need to be employed, such as viral
vectors. In the case of the tg(Grm1)EPv mouse model, it has
been reported that immunization with viral vectors before
tumor onset could fully protect from melanoma development,
and a delay in tumor growth could be achieved in tumor-
bearing mice (Xiao et al., 2011).
The self-tolerance to gp100 antigen might explain the
inability of the immune system to prevent tumor development
in the tg(Grm1)EPv mouse; however, in addition, we observed
that the tumor employs another immune escape mechanism to
suppress tumor immunity (Gajewski et al., 2013). MDSCs are a
heterogeneous population of cells derived from the myeloid
lineage endowed with strong immunosuppressive activities.
Formation of these cells is triggered under chronic
inﬂammatory conditions or in cancer, where they inﬁltrate
the affected tissue and suppress innate and adaptive immune
responses (Gabrilovich and Nagaraj, 2009). In tg(Grm1)EPv
mice, few MDSCs were detected in the skin and draining LNs
of tumor-free and early-stage tumor mice. However, a strong
inﬁltration of MDSCs could be observed in late-stage tumors.
This was not age related as old C57BL/6 mice showed no
MDSC accumulation. In addition, a shift toward more grMDSCs
as compared with moMDSCs was apparent, mimicking the
situation previously described in other murine tumor models
and in human cancer patients (Zea et al., 2005; Youn et al.,
2008). It has been reported that both subsets efﬁciently
suppress antigen-driven CD8+ T-cell proliferation in vitro
(Youn et al., 2008). We had similar ﬁndings with grMDSCs
and moMDSCs sorted from late-stage tumors that proved to be
able to suppress gp100-speciﬁc CD8+ T-cell proliferation
in vitro. Arginase-1 and iNOS have been described as key
mediators of the suppressive capacity of MDSCs in tumors
(Gabrilovich and Nagaraj, 2009). Quantitative PCR analysis of
sorted grMDSCs and moMDSCs from tumor tissue of late-stage
tg(Grm1)EPv mice revealed high mRNA levels of Arginase-1
and iNOS, and expression was conﬁrmed by ﬂow cytometric
analyses. Moreover, TGF-β, a molecule that has been linked to
tumor initiation, progression, and metastasis (Gabrilovich and
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Figure 5. Myeloid-derived suppressor cells (MDSCs) in the tumor are potent suppressors of T-cell activity. Sorted MDSC subsets from ear and tail skin of late-
stage tumor tg(Grm1)EPv mice were used to suppress CD8+ T–cell proliferation. (a) glycoprotein 100 (gp100)-speciﬁc pmel-1 CD8+ T cells (2× 104) were
puriﬁed, CFSE-labeled (0.4 μM), and cultured for 3 days together with gp100 peptide–pulsed bone marrow–derived dendritic cells (BMDCs; 1× 102). Sorted
grMDSCs (1× 104) or moMDSCs (1× 104) were added to cultures, and proliferation of T cells was measured (n=3 experiments). (b-d) Quantitative PCR analysis
of sorted granulocytic MDSC (grMDSCs) and monocytic MDSC (moMDSCs) from six late-stage tg(Grm1)EPv mice in comparison with CD45− tumor cells and
CD45+ CD11b− leukocytes was performed for (b) Arginase-1, (c) inducible nitric oxide synthase (iNOS), and (d) transforming growth factor-β (TGF-β). (e–h)
Representative histograms from skin MDSCs and summary graphs of the percentages of positive MDSCs in the skin and draining LNs from late-stage tg(Grm1)EPv
mice are shown for (e and f) Arginase-1 and (g and h) iNOS, (n=6 mice).
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Nagaraj, 2009), was also elevated at the mRNA level in sorted
MDSCs from tumor tissue. Our data suggest that grMDSCs most
likely suppress tumor immunity by iNOS, TGF-β, and to a
lesser extent with Arginase-1. The high levels of TGF-β
produced by grMDSCs but also moMDSCs have an important
role in tumor progression as reported earlier (Yang et al., 2010).
Altogether, we describe here the immune status of mice
developing melanoma spontaneously due to the ectopic
overexpression of Grm1. Despite the presence of activated
T cells with memory phenotype, the immune system fails to
mount an effective immune response to control melanoma
development. The reasons for impaired adaptive immunity
are the anergy of melanoma-antigen-associated CD8+ T cells
and the inﬁltration of immunosuppressive MDSCs to the
tumor microenvironment. This spontaneous mouse melanoma
model is highly relevant for research on human melanoma due
to the same aberrant overexpression of Grm1, which can be
observed in 60% of human melanoma samples (Pollock et al.,
2003). The relevance is further substantiated by the fact that the
immune composition of tumors is similar to that in humans,
reﬂected by the inﬁltration of immunosuppressive cells
(Senovilla et al., 2012). Taken together, these features make
this mouse model an interesting and an important tool to test
future immunotherapeutical approaches.
MATERIALS AND METHODS
Mice
Breeding pairs of the tg mouse strain tg(Grm1)EPv (Pollock et al.,
2003) were provided by Jürgen C. Becker (Department of
Dermatology and Venereology, Medical University Graz, Austria).
Tumor-free mice were used before tumor onset (2–3 months) and
compared with mice bearing early-stage tumors (5–6 months) and
late-stage tumors (8–9 months). C57BL/6 mice were originally
derived from Charles River (Sulzfeld, Germany). The T-cell receptor
tg pmel-1 mice (Overwijk et al., 2003) were kindly provided by
Thomas Tüting (Universitätsklinikum Bonn, Germany). All mouse
strains were bred at the animal facility of the Department of
Dermatology and Venereology at the Medical University of
Innsbruck. All experimental protocols were approved by the
Austrian Federal Ministry of Science and Research and performed
according to institutional guidelines.
Flow cytometric analyses of the skin and draining LN cell
suspensions
Ear skin from tumor-free and tumor-bearing tg(Grm1)EPv mice, as
well as C57BL/6 mice, was cut into small pieces and digested with
0.15mgml−1 Liberase (Roche Diagnostics, Mannheim, Germany)
and 0.12mgml−1 DNAse (Roche) for 45 min at 37 °C and pressed
through 100-μm cell strainers (BD Biosciences, Franklin Lakes, NJ).
Auricular LNs from tumor-free and tumor-bearing tg(Grm1)EPv mice,
as well as C57BL/6 mice were digested with 0.125mgml− 1
collagenase D (Roche) and 0.12mgml−1 DNAse (Roche) for
25min at 37 °C and pressed through 100-μm cell strainers (BD
Biosciences). All antibody staining steps were performed for 15 min
at 4 °C. Nonspeciﬁc FcR-mediated antibody staining was blocked by
incubation for 15 min with anti-CD16/32 Ab (2.4G2, in-house from
hybridoma supernatant and BD Biosciences). For intracellular IFN-γ
production, LN cells were restimulated with 3 μg ml−1 anti-CD3
(clone 17A2, BD Biosciences) plus 3 μgml−1 anti-CD28 (clone
37.51, BD Biosciences) for 48 h at 37 °C. Cytokine release was
blocked with 1 μgml− 1 Brefeldin A (BD Biosciences) during the last
4 h of restimulation. The cells were ﬁxed using the BD Biosciences
Cytoﬁx/Cytoperm Kit (BD Biosciences) according to the manufac-
turer’s protocol. FoxP3 staining was performed with the FoxP3/
transcription factor staining buffer set from eBioscience (San Diego,
CA). The following antibodies were used: anti-Ly-6C-FITC (clone
AL-21), anti-IFN-γ-APC (clone XMG1.2), and anti-CD3-FITC (clone
17A2) all from BD Biosciences; anti-CD45-FITC (clone 30.F11), anti-
FoxP3-PE (clone FJK-16s), and anti-iNOS-PE (clone CXNFT) all from
eBioscience; anti-CD115-PE (clone AFS98), anti-CD62L-PerCP-
Cy5.5 (clone MEL-14), anti-CD3-PerCP-Cy5.5 (clone 17A2), anti-
major histocompatibility complex II-PerCP-Cy5.5 (clone M5-
/114.15.2), anti-CD69-PE-Cy7 (clone H1.2F3), anti-CD25-PE-Cy7
(clone PC61), anti-CD44-APC (clone IM7), anti-Gr-1-APC (clone
RB6-8C5), anti-CD11b-BV421 (clone M1/70), anti-CD4-BV421
(clone RM4-5), anti-CD45-BV510 (clone 30-F11), and anti-CD8-
BV510 (clone 53-6.7) all from Biolegend (San Diego, CA); anti-
Arginase-1-PE from R&D Systems (Minneapolis, MN). Dead cells
were excluded with 7AAD (BD Biosciences) or ﬁxable viability dye
eFluor 780 (eBioscience) staining. FACS analyses were performed on
a FACS Canto II (BD Biosciences). Data analysis was performed using
FlowJo software (Tree Star, Ashland, OR).
Pentamer staining of endogeneous CD8+ T cells and IFN-γ
production
For the detection of endogenous gp100-speciﬁc CD8+ T cells, we
used an H-2Kb-KVPRNQDWL pentamer (ProImmune, Oxford, UK).
Skin and draining LNs were analyzed for the presence of H-2Kb-
KVPRNQDWL pentamer-positive CD8+ T cells. The cells were
stained according to the manufacturer’s protocol, and unspeciﬁc
pentamer binding was excluded by pregating on viable CD19−
(clone 1D3, BD Biosciences) NKp46− (clone 29A1.4, Biolegend)
cells. For the detection of IFN-γ, we incubated cell suspensions from
draining LNs with 1 μM gp100 peptide (KVPRNQDWL, Pepti-
de&Elephants, Potsdam, Germany) for 48 h at 37 °C. IFN-γ release
and antibody staining were performed as described above. For the
calculation of gp100-responsive IFN-γ+ CD8+ cells, we used this
formula: ((mean of IFN-γ+ CD8+ cells restimulated with gp100
peptide)− (mean of IFN-γ+ CD8+ cells cultured without gp100
peptide))/(mean of unstimulated pentamer+ CD8+ cells).
MDSC suppression assay
For puriﬁcation of MDSC subsets from tumor tissue, ear and tail skin
of 4–5 late-stage tumor mice were digested with 0.15mgml− 1
Liberase (Roche) and 0.12mgml−1 DNAse (Roche) for 45 min at
37 °C and pressed through 100-μm cell strainers (BD Biosciences).
CD45+ cells were enriched with a 1.119 gml− 1 Histodenz density
gradient according to the manufacturer’s protocol (Sigma-Aldrich, St.
Louis, MO). The grMDSCs and moMDSCs were puriﬁed by ﬂow
cytometric cell sorting with a FACS Aria as follows: CD45+ CD11b+
cells were distinguished with Ly-6C and Gr-1 into Gr-1inter Ly-6Chigh
moMDSCs and Gr-1high Ly-6Clow grMDSCs. CD8+ T cells were
isolated from LNs and spleen of pmel-1 mice before the onset of
spontaneous vitiligo (2–3 months). Puriﬁcation was performed with
anti-mouse-CD8-α (Ly-2) MicroBeads (Miltenyi Biotec, Bergisch
Gladbach, Germany). In order to track T-cell proliferation, cells
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were stained with 0.4 μM CFSE for 5 min at room temperature. For
suppression assays, 1× 102 BMDCs loaded with 1 μM gp100 peptide
(KVPRNQDWL, Peptide&Elephants) for 1 h at 37 °C. These cells
were cultured with 2×104 CFSE-labeled CD8+ T cells from pmel-1
mice and 2× 103 or 1× 104 sorted moMDSCs/grMDSCs for 3 days.
T-cell proliferation was measured by analysis of CFSE dilution by
ﬂow cytometry.
qPCR analysis of the skin and tumor samples
The total RNA of ear skin, tumor samples, sorted MDSC subsets,
CD45− tumor cells, and CD45+ CD11b− leukocytes was isolated
using TRIzol Reagent (Life Technologies, Carlsbad, CA) according to
the manufacturer’s instructions and analyzed by electrophoresis on
1.5% agarose gels for RNA integrity (Sigma-Aldrich) after sample
preparation in 2× RNA Loading Dye (Thermo Fischer Scientiﬁc,
Waltham, MA). Total RNA was reverse transcribed into cDNA
with random hexamers and SuperScript II Reverse Transcriptase
(Life Technologies). qPCR analysis was performed on a BioRad
CFX96 using Brilliant III Ultra-Fast qPCR and qRT-PCR Master
Mix (Agilent technologies, Boeblingen, Germany). The following
sequences for probes and primers speciﬁc for different ligands were
purchased from Life Technologies: Mm00475988_m1 (Arginase-1),
Mm00440502_m1 (iNOS), and Mm01178820_m1 (TGF-β1).
Sequences for probes and primers speciﬁc for mouse TATA-binding
protein were selected by Primer Express software (Applied Biosys-
tems) and synthesized by Microsynth (Balgach, Switzerland).
Statistical analyses
All experiments involved groups of two to six mice and were
performed at least twice with similar results. Statistical analysis was
performed using PRISM 5.0 (GraphPad Software, La Jolla, CA).
Unpaired Student’s t-test was used to determine the statistical
signiﬁcance of the mean percentages of cell types between tumor-
free and tumor-bearing mice (Figures 2a–c, 3b, 4c, 4d, 5f and h;
Supplementary Figure S3, S4 and S6 online). One-way analysis of
variance followed by post hoc Tukey’s test was used to compare
means among three or more independent groups (Figures 1a, 1b, 1c,
1e, 4a, 4b and 5a). A P-value of o0.05 was considered statistically
signiﬁcant (*), o0.01 very signiﬁcant (**), and o0.001 highly
signiﬁcant (***). The exact number of mice used per experiment
(n= number of mice) is indicated in the corresponding legend of each
ﬁgure. Error bars represent SEM (bar graph) or range from minimum
to maximum values (box and whiskers).
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